Scandinavian Tobacco Group A/S opjusterer helårsforventningerne
| Selskabsmeddelelse Nr. 17, 2020 |
København, den 14. august 2020
Scandinavian Tobacco Group A/S opjusterer helårsforventningerne
De negative effekter af COVID-19 pandemien på Scandinavian Tobacco Group´s forretning har været mindre end tidligere antaget da tobaksforbruget på tværs af markeder og produktkategorier har været særdeles robust.
Den nuværende ændring i forbrugeradfærden i USA som følge af at flere arbejder hjemme har medvirket til et tilsyneladende samlet stigende forbrug af håndrullede cigarer og en stærk vækst i online-forretningen. Kombineret med en stærkere end ventet robusthed i salget af maskinfremstillede cigarer og røgtobak – samt et fortsat stærkt fokus på omkostningerne – kan Scandinavian Tobacco Group for første halvår 2020 præsentere en organisk vækst i nettoomsætningen på 4,9%, en organisk EBITDA vækst på 21% og frie pengestrømme før virksomhedskøb på DKK 547 mio. Den finansielle udvikling er fortsat positivt påvirket af lageropbygning i visse markeder. Dette vil påvirke resultaterne i andet halvår.
Mens gennemsigtigheden for de finansielle forventninger fortsat er lavere end normalt, så forventes det nu at ændringen i forbrugeradfærden i USA vil fortsætte året ud og baseret på år til dato finansielle resultater, inklusive en stærk udvikling i juli måned, en vellykket start på integrationen af Agio Cigars samt at der ikke indtræffer større forstyrrelser i vores forsyningskæde, så ændres Gruppens helårsforventninger som følger:
- EBITDA: Organisk vækst >9% (tidligere: >2%)
- Frie pengestrømme før virksomhedskøb: >DKK 1000 mio. (tidligere: ~DKK 850 mio.)
Regnskabet for første halvår fremlægges den 28. august 2020.
For yderligere oplysninger kontakt venligst:
Investorhenvendelser: Torben Sand, Head of Investor Relations,
telefon: +45 5084 7222 eller torben.sand@st-group.com
Pressehenvendelser: Simon Mehl Augustesen, Director of Group Communications,
telefon: +1 484-379-8725 eller simon.augustesen@st-group.com
Vedhæftet fil
Information om GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire
Leasinvest Real Estate SCA: Important lease in the building Mercator in Luxembourg30.9.2020 17:40:00 CEST | Press release
New lease for a floor in the building Mercator Leasinvest Real Estate has just concluded a new lease for 1,560 m² with CHL – ‘Centre Hospitalier de Luxembourg’, in the building Mercator located Route d'Arlon 110-112 in the Grand Duchy of Luxembourg. This new lease concretises the in-principle agreement already announced in the half-year financial report published on 19 August 2020. The rent price amounts to € 22/m²/month and the contract starts tomorrow, 1 October 2020. The building Mercator has a total surface area of 8,641 m² of offices, spread across 5 floors and comprises 104 parking spaces, and benefits from an exceptional location in the capital of the Grand Duchy along the Route d’Arlon, one of the main axes to the City of Luxembourg. Moreover, the building Mercator is located nearby Luxembourg’s main hospital, around which an important number of (para)medical businesses are located. This transaction was realised with the intervention of Cushman & Wakefield. Michel Van Geyte, CE
Ress Life Investments A/S: Ress Life Investments A/S publishes Net Asset Value (NAV)30.9.2020 17:05:00 CEST | Press release
Ress Life Investments Holbergsgade 14, 2 tv DK-1057 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 30 September 2020 Corporate Announcement 36/2020 Ress Life Investments A/S publishes Net Asset Value (NAV). Ress Life Investments A/S publishes the Net Asset Value (NAV) per share and performance data as of 15 September 2020. NAV per share in USD: 2064.01 NAV per share in EUR: 1735.63 The performance during the first half of September was -0.49% in USD. The year-to-date net performance is 5.37% in USD. Assets under management (AUM) was 215.0 million US dollars. Questions related to this announcement can be made to the company's AIF-manager, Resscapital AB. Contact person: Gustaf Hagerud gustaf.hagerud@resscapital.com Tel + 46 8 545 282 27 Note: The terms for subscription of shares, minimum subscription amount and redemption of shares are provided in the Articles of Association, Information Brochure and in the Key Investment Information Docume
Vaisala’s financial information and Annual General Meeting in 202130.9.2020 17:00:00 CEST | Press release
Vaisala Corporation Stock exchange release September 30, 2020 at 6:00 p.m. EEST Vaisala’s financial information and Annual General Meeting in 2021 Vaisala Corporation will publish its Financial Statement Release, Half Year Financial Report and two Interim Reports during 2021 as follows: - February 19, 2021: Financial Statement Release 2020 - April 29, 2021: Interim Report January–March 2021 - July 23, 2021: Half Year Financial Report 2021 - October 28, 2021: Interim Report January–September 2021 The Annual Report 2020 will be published at vaisala.com by the end of week 9. Vaisala Corporation’s Annual General Meeting is scheduled for Tuesday, March 30, 2021. The Board of Directors of the company will convene the meeting. More information Paula Liimatta, Business Controller and Head of Investor Relations Tel. +358 40 580 3521 Distribution Nasdaq Helsinki Key media vaisala.com Vaisala is a global leader in environmental and industrial measurement. Building on over 80 years of experience,
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING30.9.2020 16:20:00 CEST | Press release
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING 2020-10-02 Transaction type:SEK CreditTender date:2020-10-02Time for submission of bids:10.30-11.00 (CEST)Payment date:2020-10-06Final repayment date2024-10-07Offered volume:50 billion SEKMinimum bid amount:10 million SEKMaximum bid amount:12.5 billion SEKMaximum number of bids from each participant: 1Interest rate:0.00 %Additional interest rate:0.10 per cent ALL APPROVED COUNTERPARTIES ARE INVITED TO SUBMIT VOLUME BIDS TO THE RIKSBANK (46-8-6966970) BY 11.00 ON OCTOBER 2 2020, AT THE LATEST. CONFIRMATION ON E-MAIL: eol@riksbank.se Result of the auction will be published at 11.30 (CEST) on Tender date. Complete terms and conditions can be retrieved at http://www.riksbank.se
Auction details government bonds30.9.2020 16:20:00 CEST | Press release
Auction date October 7, 2020 Maturity date Loan ISIN code Coupon Issue volume, SEK million 2028-05-12 1060 SE0009496367 0.75% 4,000 2032-06-01 1056 SE0004517290 2,25% 1,000 Settlement date October 9, 2020 Bids have to be entered by 11.00 on October 7, 2020 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 FO@riksgalden.se
Change in numbers of shares and votes in Saniona AB (publ)30.9.2020 16:00:00 CEST | Press release
PRESS RELEASE September 30, 2020 During September, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to the exercising of warrants of series TO 2. As of September 30, 2020, the registered number of shares and votes in Saniona amounts to 62,372,831. For more information, please contact Trista Morrison, Chief Communications Officer. Mobile + 1 (858) 229 1738. Email: trista.morrison@saniona.com This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 4 p.m. CET on September 30, 2020. About Saniona Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments f